Email this article 
Rare clinical observation of pronounced response to immunotherapy in a patient with anaplastic thyroid cancer
- Authors: Vontlaya D.M.1, Stryapikhina O.V.2, Egorin A.A.1, Logvinenko A.V.1, Tamrazov R.I.1
-
Affiliations:
- Multidisciplinary clinical medical center “Medical city”
- Tyumen State Medical University, Ministry of Health of Russia
- Issue: Vol 14, No 1 (2024)
- Pages: 63-69
- Section: CASE REPORT
- Published: 28.06.2024
- URL: https://ogsh.abvpress.ru/jour/article/view/970
- DOI: https://doi.org/10.17650/2222-1468-2024-14-1-63-69
- ID: 970
Cite item
Full Text
Abstract
Anaplastic thyroid cancer is the rarest and the most aggressive form of thyroid cancer. It comprises 1-2 % of all cases and is characterized by rapid growth. median survival of patients with this pathology is about 5 months. Clinical manifestations of the disease are rapid deformation in the neck area, progressive respiratory distress, and dysphagia.
The article describes a clinical case of a response of unresectable, BRAF-negative, PD-L1-positive (programmed death-ligand 1) anaplastic thyroid cancer to immunotherapy with pembrolizumab.
About the authors
D. M. Vontlaya
Multidisciplinary clinical medical center “Medical city”
Author for correspondence.
Email: mirhaleeva@mail.ru
Dinara M. Vontlaya.
32 Barnaul'skaya St., Tyumen 625000
Russian FederationO. V. Stryapikhina
Tyumen State Medical University, Ministry of Health of Russia
Email: fake@neicon.ru
54 Odesskaya St., Tyumen 625023
Russian FederationA. A. Egorin
Multidisciplinary clinical medical center “Medical city”
Email: fake@neicon.ru
ORCID iD: 0000-0002-1126-6133
32 Barnaul'skaya St., Tyumen 625000
Russian FederationA. V. Logvinenko
Multidisciplinary clinical medical center “Medical city”
Email: fake@neicon.ru
32 Barnaul'skaya St., Tyumen 625000
Russian FederationR. I. Tamrazov
Multidisciplinary clinical medical center “Medical city”
Email: fake@neicon.ru
ORCID iD: 0000-0002-6831-6971
32 Barnaul'skaya St., Tyumen 625000
Russian FederationReferences
- Luk'yanov S.A., Sergiyko S.V., Titov S.E. et al. New opportunities for preoperative diagnosis of anaplastic thyroid cancer. Opukholi golovy i shei = Head and Neck Tumors 2021;11(1):34-40. (In Russ.). doi: 10.17650/2222-1468-2021-11-1-34-40
- Pylev A.L., Zhandarova A.A., Petrov K.S. et al. Anaplastic thyroid cancer. Is there a light at the end of the tunnel? Opukholi golovy i shei = Head and Neck Tumors 2020;10(1):10-9. (In Russ.). doi: 10.17650/2222-1468-2020-10-1-10-19
- Nikiforovich P.A., Rumyantsev P.O., Sleptsov I.V. et al. Treatment of BRAFV600E-positive anaplastic thyroid carcinoma: case report. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology журнал 2020;19(5):131-44. (In Russ.). doi: 10.21294/1814-4861-2020-19-5-131-144
- Mudunov A.M., Pheshkhova B.G., Zeynalova P.A. et al. The difficulties of diagnosis and features of the clinical course of anaplastic thyroid cancer. A clinical case. MD-Onco 2022;2(4):22-6. (In Russ.). doi: 10.17650/2782-3202-2022-2-4-22-26
- Samsonov R., Burdakov V., Shtam T. et al. Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer. Tumour Biol 2016;37(9):12011-21. doi: 10.1007/s13277-016-5065-3
- Volante M., Lam A.K., Papotti M. et al. Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know? Endocr Pathol 2021;32(1):63-76. doi: 10.1007/s12022-021-09665-2
- Santhanam P., Khthir R., Solnes L.B., Ladenson P.W. The relationship of BRAFv600e mutation status to FDG PET/CT avidity in thyroid cancer: a review and meta-analysis. Endocr Pract 2018;24(1):21-6. doi: 10.4158/EP-2017-0080
- FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAFV600E mutation. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenibplus-trametinib-anaplastic-thyroid-cancer-braf-v600e-mutation.
- Naing A., Gainor J.F., Gelderblom H. et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. J Immunother Cancer 2020;8(1):e000530. doi: 10.1136/jitc-2020-000530
- Cabanillas M.E., Dadu R., Iyer P. et al. Acquired secondary RAS mutation in BRAFV600E-mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid 2020;30(9):1288-96. doi: 10.1089/thy.2019.0514
- Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64.
- Edwards S.C., Hoevenaar W.H.M., Coffelt S.B. Emerging immunotherapies for metastasis. Br J Cancer 2021;124(1):37-48. doi: 10.1038/s41416-020-01160-5
- Larkin J., Chiarion-Sileni V., Gonzalez R. et al. Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma. N Engl J Med 2015;373(1):23-34. doi: 10.1056/NEJMoa1504030
- Borel C., Jung A.C., Burgy M. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Cancer 2020;12(9):2691. doi: 10.3390/cancers12092691
Supplementary files
